Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.55 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RHEB | Q15382 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994974 | 0.84 | RHEB (0.44) | AURKATPX2KDM4EALDH1A1HPGD | |
| SCHEMBL26111372 | 0.80 | RHEB (0.41) | AURKATPX2KDM4EALDH1A1HPGD | |
| SCHEMBL29507057 | 0.80 | NPC1 (0.45) | KDM4EHSD17B10RHEBAHRXDH | |
| SCHEMBL18387753 | 0.80 | RHEB (0.41) | AURKATPX2KDM4EALDH1A1HPGD | |
| SCHEMBL3546474 | 0.80 | NPC1 (0.45) | KDM4EHSD17B10RHEBAHRXDH | |
| SCHEMBL7163885 | 0.80 | AURKA (0.56) | AURKATPX2KDM4EALDH1A1HPGD | |
| SCHEMBL2806054 | 0.80 | AURKA (0.56) | AURKATPX2KDM4EALDH1A1HPGD | |
| SCHEMBL30446838 | 0.80 | AURKA (0.56) | AURKATPX2KDM4EALDH1A1HPGD | |
| SCHEMBL22990273 | 0.79 | PARP1 (0.50) | AURKATPX2KDM4EALDH1A1HPGD | |
| SCHEMBL29698318 | 0.79 | PARP1 (0.50) | AURKATPX2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-12516065-B2 | Tertiary alcohols as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| EP-4524133-A2 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| EP-3939658-B1 | SUBSTITUTED BENZOPYRROLE AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-09-05 | — | — | US | disclosed |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| EP-3322702-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | Mission Therapeutics Limited (GB) | 2018-05-23 | — | — | EP | disclosed |
| WO-2017009650-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-01-19 | — | — | WO | disclosed |
| WO-2017009650-A1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-01-19 | — | — | WO | disclosed |
| US-7662824-B2 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7662824-B2 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-7662824-B2 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-16 | — | — | US | disclosed |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| WO-2006101937-A1 | ACYLHYDRAZONES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228498-A1 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS | PIK3R5, PIK3R1, PIK3CD | AURKA 3374/4885TPX2 1268/4885KDM4E 3139/4885 |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | AURKA 4367/4885TPX2 205/4885KDM4E 2522/4885 |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | AURKA 4367/4885TPX2 205/4885KDM4E 2522/4885 |
| US-20070066610-A1 | Acylhydrazones as kinase modulators | MET, ERBB2, ERBB3 | AURKA 117/4885TPX2 1959/4885KDM4E 657/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | AURKA 4287/4885TPX2 278/4885KDM4E 1536/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | AURKA 3746/4885TPX2 1403/4885KDM4E 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.